• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by West Pharmaceutical Services Inc.

    3/21/25 4:07:14 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    DEFA14A 1 tmb-20250320xdefa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.           )

    ​

    Filed by the Registrant   x

    Filed by a Party other than the Registrant  ¨

    Check the appropriate box:

    ¨

    Preliminary Proxy Statement

    ¨

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    ¨

    Soliciting Material under §240.14a-12

      

     

    West Pharmaceutical Services, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    x

    No fee required.

    ¨

    Fee paid previously with preliminary materials.

    ¨

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

    ​


    GRAPHIC

    Your Vote Counts! WEST PHARMACEUTICAL SERVICES, INC. You invested in WEST PHARMACEUTICAL SERVICES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 6, 2025. Vote Virtually at the Meeting* May 6, 2025 9:30 AM EDT Virtually at: www.virtualshareholdermeeting.com/WST2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V62352-P26361 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 22, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. WEST PHARMACEUTICAL SERVICES, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 2025 Annual Meeting Vote by May 5, 2025 11:59 PM EDT. For shares held in a Plan, vote by May 1, 2025 11:59 PM EDT.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V62353-P26361 1. Election of Directors; Nominees: 1a. Mark A. Buthman For 1b. William F. Feehery For 1c. Robert F. Friel For 1d. Eric M. Green For 1e. Janet B. Haugen For 1f. Thomas W. Hofmann For 1g. Molly E. Joseph For 1h. Deborah L. V. Keller For 1i. Myla P. Lai-Goldman For 1j. Stephen H. Lockhart For 1k. Douglas A. Michels For 1l. Paolo Pucci For 2. Advisory vote to approve named executive officer compensation; For 3. Amend and Restate Our Amended and Restated Articles of Incorporation to Add a Right For Shareholders to call a Special Meeting; For 4. Amend and Restate Our 2016 Omnibus Incentive Compensation Plan; and For 5. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $WST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

    Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system. West Synchrony S1 PFS system provides a broad product po

    1/20/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on West Pharm with a new price target

    Morgan Stanley initiated coverage of West Pharm with a rating of Equal-Weight and set a new price target of $285.00

    12/2/25 8:36:52 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

    Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00

    9/15/25 8:12:22 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Haugen Janet Brutschea

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    1/5/26 12:37:29 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:33:41 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Finch Norman D. Jr.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:32:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    SEC Filings

    View All

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    2/12/26 7:21:40 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

    SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    10/31/25 11:41:37 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 4:14:52 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Declares Quarterly Dividend

    EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug devel

    12/10/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care